Introduction:
Six major pharmaceutical companies, including Dr. Reddy’s Laboratories and Aurobindo Pharma, signed MoUs with the state government to invest ₹5,260 crore in eco-friendly pharma units at Pharma City. This initiative is projected to generate 12,490 job opportunities.
It reflects commitment to sustainable industrial development and positions Pharma City as a global pharmaceutical hub. Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu emphasized the importance of this collaboration during discussions with company representatives.
The MoUs signify a pledge to establish eco-friendly “green pharma” manufacturing facilities within Pharma City, envisioned as a comprehensive hub dedicated to sustainable pharmaceutical innovation and development.
Dr Reddy’s Laboratories
On November 27, 2024, Dr. Reddy’s Laboratories Ltd opened at ₹1217.35, down 0.76% from its previous close of ₹1208.90. The stock hit a high of ₹1217.35 and a low of ₹1197.70. The stock closed at ₹1200.50, reflecting a 0.69% decrease. The market cap stands at ₹1,00,163.20 crore.
Dr Reddy’s Laboratories will establish advanced facilities for injectables and biosimilars production. These units will focus on pioneering healthcare solutions while supporting Pharma City’s eco-friendly and innovation-driven pharmaceutical manufacturing goals.
Dr. Reddy’s Laboratories (NSE: DRREDDY) is a global pharmaceutical giant offering a broad range of generic medicines, biosimilars, and over-the-counter products. It is dedicated to improving healthcare access and affordability worldwide.
Laurus Labs
On November 27, 2024, Laurus Labs Ltd opened at ₹546.00, down 0.35% from its previous close of ₹546.25. The stock hit a high of ₹554.90 and a low of ₹541.70. The stock closed at ₹544.30, reflecting a 0.36% decrease. The market cap stands at ₹29,346.44 crore.
Laurus Labs plans to set up a formulation manufacturing unit in Pharma City. The facility will focus on producing advanced pharmaceutical formulations, enhancing its position as a leader in the healthcare sector while supporting the state’s industrial growth.
Laurus Labs (NSE: LAURUSLABS) is a globally recognized pharmaceutical company focusing on APIs, formulations, and contract development. Its strong R&D capabilities and sustainable practices make it a trusted partner in healthcare innovation and delivery.
Aurobindo Pharma
On November 27, 2024, Aurobindo Pharma Ltd opened at ₹1237.95, down 0.74% from its previous close of ₹1229.15. The stock hit a high of ₹1237.95 and a low of ₹1218.65. The stock closed at ₹1223.95, reflecting a 0.42% decrease. The market cap stands at ₹71,087.21 crore.
Aurobindo Pharma will develop a formulation manufacturing unit within Pharma City. This venture aims to expand its manufacturing capabilities while aligning with the state government’s vision of a sustainable and pollution-free pharmaceutical development ecosystem.
Aurobindo Pharma (NSE: AUROPHARMA) is one of India’s largest pharmaceutical manufacturers, producing APIs and generic drugs. It operates globally, with a robust pipeline of products across various therapeutic segments, emphasizing affordability and quality.
Also Read: Petrochemical stock jumps 5% after it receives supply orders from BPCL and IOCL
Gland Pharma
On November 27, 2024, Gland Pharma Ltd opened at ₹1730.05, down 0.56% from its previous close of ₹1739.85. The stock hit a high of ₹1758.35 and a low of ₹1720.30. The stock closed at ₹1727.10, reflecting a 0.73% decrease. The market cap stands at ₹28,454.27 crore.
Gland Pharma will invest in an R&D center alongside facilities for injectables and drug substance manufacturing. These initiatives will bolster innovation and production capacities, strengthening Pharma City’s position as a global hub for pharmaceutical excellence.
Gland Pharma (NSE: GLAND) is a leading injectables-focused pharmaceutical company with expertise in complex products. It caters to global markets with its high-quality formulations and manufacturing capabilities, driven by advanced research and innovation.
Hetero Labs
Hetero Labs is set to build a finished dosage and injectable manufacturing plant in Pharma City. This project reflects its commitment to enhancing pharmaceutical accessibility and innovation, contributing significantly to the region’s industrial and socio-economic progress.
Hetero Labs is a major pharmaceutical manufacturer known for its APIs, biosimilars, and finished formulations. Focused on innovation and accessibility, it serves patients globally with high-quality and affordable healthcare solutions. The company remains unlisted in the stock market.
MSN Group
MSN Group will establish a state-of-the-art manufacturing facility and a dedicated R&D center in Pharma City. This initiative underscores its commitment to innovation and sustainable pharmaceutical production, contributing to the eco-friendly goals of the green pharma hub.
MSN Group is a leading Indian pharmaceutical company specializing in active pharmaceutical ingredients (APIs) and finished formulations. The company emphasizes R&D and innovation to provide affordable healthcare solutions. This company is not yet listed on the stock market.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
